Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.53 and traded as low as $3.42. Cryo-Cell International shares last traded at $3.45, with a volume of 2,075 shares.

Cryo-Cell International Trading Up 1.8%

The firm has a market capitalization of $27.81 million, a PE ratio of -10.45 and a beta of 0.48. The firm has a 50-day moving average of $3.52 and a two-hundred day moving average of $3.53.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $7.68 million during the quarter.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent quarter. 10.44% of the stock is owned by institutional investors and hedge funds.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.